Northern Trust Corp Decreases Holdings in Glaukos Corporation $GKOS

Key Points

• Northern Trust Corp reduced its holding in Glaukos Corporation by 1.5%, ending the most recent quarter with 569,729 shares valued at approximately $56 million.
• Glaukos reported a quarterly EPS of -$0.24, beating analysts' expectations and showing a 29.7% increase in revenue year-over-year.
• Equities analysts have mixed ratings on Glaukos, with an average price target of $127.42 and varying opinions from "Strong Buy" to "Sell."

Northern Trust Corp cut its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 1.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 569,729 shares of the medical instruments supplier's stock after selling 8,944 shares during the period. Northern Trust Corp owned about 1.00% of Glaukos worth $56,073,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Glaukos by 9.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 312,314 shares of the medical instruments supplier's stock worth $46,828,000 after purchasing an additional 26,540 shares during the period. Stifel Financial Corp lifted its holdings in shares of Glaukos by 2.6% during the fourth quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock worth $651,000 after purchasing an additional 111 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Glaukos by 13.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,182 shares of the medical instruments supplier's stock worth $5,276,000 after purchasing an additional 4,227 shares during the period. Coldstream Capital Management Inc. acquired a new position in shares of Glaukos during the fourth quarter worth $208,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Glaukos during the fourth quarter worth $1,903,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Down 0.7%

GKOS traded down $0.70 during trading on Friday, hitting $95.86. 488,453 shares of the company's stock were exchanged, compared to its average volume of 846,228. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The business's 50 day moving average is $95.62 and its two-hundred day moving average is $99.17. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The stock has a market cap of $5.50 billion, a P/E ratio of -58.10 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The firm had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. The business's revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on GKOS shares. Wells Fargo & Company lifted their price target on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Morgan Stanley dropped their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Zacks Research lowered shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. UBS Group boosted their target price on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Finally, Mizuho set a $130.00 target price on shares of Glaukos in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.